Contraindicated (1)bortezomib will improve the level or result of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or reasonable CYP2C19 inhibitors may well improve mavacamten systemic exposure, leading to heart failure resulting from systolic dysfunction. fluconazole will improve the stage or result of bortezomib by affecting hepatic/intestinal enzym... https://mitoxantrone91345.shoutmyblog.com/26512109/the-smart-trick-of-verteporfin-that-nobody-is-discussing